Medinoah Company, Inc.

Established in 2008, Medinoah is a global leading Contract Research Organization (CRO)/Contract Development and Manufacturing Organization (CDMO), which provides integrated solutions throughout small molecule drug discovery, development and manufacturing. Driven by its technical strength and expertise, Medinoah has a demonstrated track record of helping clients to maximize their pipeline value with best quality and advance their drug discovery projects in a timely and cost-effective manner. Our Offer • Medicinal Chemistry/Synthetic Chemistry • Process Development & Manufacturing of API/RSM • Analytical Development in all stages of a drug lifecycle • Regulatory Filings, IND/NDA/ANDA in compliance with USFDA, EMA and China FDA etc. Our History Medinoah story starts in 2008. With 15 years of history, Medinoah has grown to become a premier R&D service provider for pharmaceutical & biotech companies. 2008 -- Founded in Suzhou (China) and Branford, CT 2010 -- Launched Process R&D service 2012 -- Launched ADC R&D service 2013 -- One of the earliest CROs in Targeting Protein Degradation (TPD) 2016 -- Launched Analytical & Quality Research service 2020 -- Pilot plant (cGMP) ready for production 2021 -- Closed series A round of funding 2022 -- Manufacturing plant ready for production 2023 -- Closed series B round of funding Medinoah Key Figures • 400 Employees • 180 Scientists, Engineers, and other Experts • 2 R&D Centers • 1 cGMP Pilot Plant • 1 cGMP Manufacturing Sites